NATCO Pharma Limited (NSE:NATCOPHARM)
1,015.90
-159.90 (-13.60%)
May 29, 2026, 3:30 PM IST
NATCO Pharma Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 15,509 | 1,200 | 704 | 1,319 | 1,111 |
Short-Term Investments | 5,782 | 23,699 | 13,208 | 6,612 | 6,488 |
Cash & Short-Term Investments | 21,291 | 24,899 | 13,912 | 7,931 | 7,599 |
Cash Growth | -14.49% | 78.97% | 75.41% | 4.37% | -7.07% |
Accounts Receivable | 8,812 | 12,466 | 11,889 | 8,561 | 6,206 |
Other Receivables | - | 1,045 | 706 | 351 | 545 |
Receivables | 8,910 | 13,605 | 12,685 | 9,014 | 6,855 |
Inventory | 9,085 | 8,494 | 7,917 | 8,089 | 8,620 |
Prepaid Expenses | - | 305 | 289 | 283 | 326 |
Other Current Assets | 11,237 | 5,397 | 5,432 | 4,686 | 1,467 |
Total Current Assets | 50,523 | 52,700 | 40,235 | 30,003 | 24,867 |
Property, Plant & Equipment | 28,391 | 26,573 | 24,350 | 23,034 | 23,084 |
Long-Term Investments | 25,489 | 1,528 | 959 | 873 | 1,044 |
Goodwill | 630 | 574 | 560 | 552 | 507 |
Other Intangible Assets | 1,943 | 2,087 | 1,371 | 1,326 | 822 |
Long-Term Deferred Tax Assets | 2,326 | 501 | 194 | - | - |
Other Long-Term Assets | 1,435 | 2,345 | 1,394 | 786 | 767 |
Total Assets | 110,737 | 86,308 | 69,063 | 56,574 | 51,091 |
Accounts Payable | 4,093 | 2,749 | 2,355 | 2,638 | 1,618 |
Accrued Expenses | - | 977 | 843 | 691 | 569 |
Short-Term Debt | 6,064 | 2,731 | 3,781 | 1,744 | 4,205 |
Current Portion of Leases | 33 | 17 | 27 | 6 | 35 |
Current Income Taxes Payable | 5 | 790 | 323 | 101 | 9 |
Other Current Liabilities | 6,614 | 2,171 | 2,399 | 1,651 | 668 |
Total Current Liabilities | 16,809 | 9,435 | 9,728 | 6,831 | 7,104 |
Long-Term Debt | 1,000 | - | - | - | - |
Long-Term Leases | 42 | 46 | 53 | 11 | 80 |
Pension & Post-Retirement Benefits | - | 181 | 266 | 468 | 574 |
Long-Term Deferred Tax Liabilities | 2 | 2 | 2 | 124 | 301 |
Other Long-Term Liabilities | 673 | 521 | 483 | 402 | 396 |
Total Liabilities | 18,526 | 10,185 | 10,532 | 7,836 | 8,455 |
Common Stock | 358 | 358 | 358 | 365 | 365 |
Additional Paid-In Capital | - | 12,019 | 12,019 | 14,065 | 14,078 |
Retained Earnings | - | 63,061 | 45,252 | 33,518 | 27,261 |
Comprehensive Income & Other | 91,853 | 632 | 902 | 790 | 932 |
Total Common Equity | 92,211 | 76,070 | 58,531 | 48,738 | 42,636 |
Minority Interest | - | 53 | - | - | - |
Shareholders' Equity | 92,211 | 76,123 | 58,531 | 48,738 | 42,636 |
Total Liabilities & Equity | 110,737 | 86,308 | 69,063 | 56,574 | 51,091 |
Total Debt | 7,139 | 2,794 | 3,861 | 1,761 | 4,320 |
Net Cash (Debt) | 14,152 | 22,105 | 10,051 | 6,170 | 3,279 |
Net Cash Growth | -35.98% | 119.93% | 62.90% | 88.17% | -38.57% |
Net Cash Per Share | 79.02 | 123.42 | 56.00 | 33.80 | 17.98 |
Filing Date Shares Outstanding | 179.08 | 179.11 | 179.11 | 182.47 | 182.52 |
Total Common Shares Outstanding | 179.08 | 179.11 | 179.11 | 182.47 | 182.52 |
Working Capital | 33,714 | 43,265 | 30,507 | 23,172 | 17,763 |
Book Value Per Share | 514.92 | 424.71 | 326.79 | 267.10 | 233.60 |
Tangible Book Value | 89,638 | 73,409 | 56,600 | 46,860 | 41,307 |
Tangible Book Value Per Share | 500.55 | 409.85 | 316.01 | 256.81 | 226.31 |
Land | - | 5,265 | 3,692 | 2,855 | 2,641 |
Buildings | - | 11,090 | 11,080 | 10,593 | 9,734 |
Machinery | - | 19,485 | 18,340 | 17,616 | 16,798 |
Construction In Progress | - | 2,254 | 1,373 | 643 | 1,295 |